Neuromuscular HOMEepAGE

neuromuscular.wustl.edu

/

IV. Interpretations of Confirmed Positive anti-MAG Results

Immune/Antibody

View full entry on WUSTL Neuromuscular

antibody/mag.html#IV. Interpretations of Confirmed Positive anti-MAG Results

Overview

From WUSTL Neuromuscular

Diagnosis Provide independent support for presence of immune-mediated sensory-motor polyneuropathy. Distinguish anti-MAG polyneuropathy from chronic inflammatory demyelinating polyneuropathy (CIDP). Treatment: Indicate that Combined cyclophosphamide and plasma exchange treatment may produce functionally useful improvement in strength, sensation, and gait. Other therapy such as prednisone, IVIg, or plasma exchange is unlikely to be of benefit

Related Conditions

Shared genes

Antibodies vs Glycolipids & Glycoproteins

Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)

HDSDISACCHARIDEMAG

I. Clinical Indications for Measurement of anti-MAG antibodies

II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies

III. Testing Laboratory Standards for anti-MAG Antibodies.

IV. Positive Result: Clinical Utility and Interpretations

Monoclonal Gammopathies of Unknown Significance (& Other)

Myelin Glycoproteins

External Resources

WUSTL Neuromuscular

Washington University Disease Center

Biomedical Literature

NCBI Expert-Authored Reviews

Portal for Rare Diseases

National Organization for Rare Disorders

Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.